Teng Fei

Title: Teng Fei: Innovator in Anti-PD-L1 Antibodies

Introduction

Teng Fei is a prominent inventor based in Suzhou, China. He has made significant contributions to the field of biotechnology, particularly in the development of anti-PD-L1 antibodies. With a total of 2 patents, his work is paving the way for advancements in cancer treatment.

Latest Patents

Teng Fei's latest patents focus on isolated PD-L1 antibodies. These antibodies exhibit a unique characteristic where their binding to PD-L1 at acidic pH is substantially lower than at neutral pH under the same assay conditions. Additionally, he has developed an isolated PD-L1 antibody that is not pH dependent in its binding to PD-L1. His patents also include pharmaceutical compositions of these antibodies, encoding polynucleotides, expression vectors, and isolated host cells. Furthermore, he has provided methods for treating PD-L1 associated conditions using these innovative antibodies.

Career Highlights

Throughout his career, Teng Fei has worked with notable companies, including Suzhou Transcenta Therapeutics Co., Ltd. His expertise in the field has allowed him to contribute to groundbreaking research and development in antibody therapies.

Collaborations

Teng Fei has collaborated with esteemed colleagues such as Xueming Qian and Zhen Li. These partnerships have further enhanced his research and innovation in the biotechnology sector.

Conclusion

Teng Fei's contributions to the development of anti-PD-L1 antibodies represent a significant advancement in the fight against cancer. His innovative work continues to inspire future research in the field.